bioMérieux Invests in Plair to Advance Real-Time Environmental Monitoring for Pharmaceutical Industry
By the bioMérieux Editors | Reading time: 2 min
PUBLICATION DATE: March 23, 2026
bioMérieux announces an investment of more than one million Swiss Francs in Plair, a scale-up company offering a breakthrough solution for real-time microbial detection and air sampling.
As part of our commitment to advancing environmental control to help improve patient and consumer health, bioMérieux invested in Plair, a Company headquartered in Geneva, Switzerland. Plair’s flagship innovation, RAPID-C+, is a unique real-time viable particle counter that sets a new industry standard in pharmaceutical environmental monitoring. RAPID-C+ is already commercially available.
This partnership reinforces bioMérieux’s commitment to driving innovation in environmental monitoring and supporting the evolving needs of the pharmaceutical industry.
RAPID-C+ combines real-time counting of viable and total particles with certified continuous sampling on standard agar media, enabling microbial identification and supporting faster, more-informed decision making in cleanroom environments.
As part of this collaboration, bioMérieux Senior Vice President of Pharma Quality Control Michael Reynier will join Plair’s Board of Directors.
“Our investment in Plair is a strategic step forward in our ambition to be the partner of choice for advancing pharmaceutical quality control,” said Reynier. “RAPID-C+ is a breakthrough innovation that complements our portfolio and supports our customers in delivering critical therapies quickly and safely to patients.”
“An investment from a global leader like bioMérieux brings unique synergies to Plair, creating significant value for all our stakeholders, partners, and RAPID-C+ users,” said Plair CEO Denis Kiselev. “The acceleration of the bio-fluorescent particle counter market demands that quality managers and microbiologists receive clear regulatory support and scientific guidance to adopt this new method. We believe this endorsement by bioMérieux will become a strong signal to the industry, ultimately resulting in better, safer medicines for patients.”
This investment reflects bioMérieux’s strategy to diversify and strengthen our Pharma Quality Control offering, which is built on a partner-first approach and over 60 years of scientific excellence. With a global presence in more than 160 countries and a team dedicated to innovation, bioMérieux is recognized as a trusted reference by pharmaceutical leaders worldwide.
